CStone Pharmaceuticals’ sugemalimab gains ESMO I,A recommendation; consolidation treatment duration rises to 24 months for stage III NSCLC

Reuters03-25 17:16
<a href="https://laohu8.com/S/02616">CStone Pharmaceuticals</a>’ sugemalimab gains ESMO I,A recommendation; consolidation treatment duration rises to 24 months for stage III NSCLC
  • Sugemalimab gained an ESMO guideline recommendation at level [I, A] for consolidation treatment in stage III non-small cell lung cancer, a milestone that could strengthen its positioning against established immuno-oncology options in Europe.
  • The update adds Sugemalimab to ESMO’s “Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline,” which may support market access momentum across the EU and other markets.
  • ESMO’s recommendation specifies use for eligible stage III NSCLC patients after concurrent or sequential chemoradiotherapy, with treatment duration capped at no more than 24 months.
  • The company said it has signed four commercialization collaborations across Europe, the Middle East and Africa, and Latin America, while its commercialization network has expanded to more than 60 countries and regions.
  • Market access filings have been approved or are under review in more than 10 countries, extending the product’s global commercialization runway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12066534), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment